T Cell Acute Lymphoblastic Leukemia Lymphoma clinical trials

Explore recruiting t cell acute lymphoblastic leukemia lymphoma clinical trials.

Recruiting t cell acute lymphoblastic leukemia lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

T Cell Acute Lymphoblastic Leukemia Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Safety and efficacy of hCD1a-CAR T (OC-1) therapy, in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL)_CARxALL

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Phase I/II study of anti-CD7 Chimeric Antigen Receptor-Expressing T cells in pediatric patients/young adult affected by relapsed/refractory CD7+ T-cell Acute Lymphoblastic Leukemia/Lymphoma

Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Long-term Follow-up study for relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL) patients previously treated with OC-1 cells.

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

T Cell Acute Lymphoblastic Leukemia Lymphoma trials by city

T Cell Acute Lymphoblastic Leukemia Lymphoma clinical trials

Recruiting t cell acute lymphoblastic leukemia lymphoma studies right now

Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia

Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma

A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).

Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL

Also recruiting in Europe

Safety and efficacy of hCD1a-CAR T (OC-1) therapy, in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL)_CARxALL

Phase I/II study of anti-CD7 Chimeric Antigen Receptor-Expressing T cells in pediatric patients/young adult affected by relapsed/refractory CD7+ T-cell Acute Lymphoblastic Leukemia/Lymphoma

Long-term Follow-up study for relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL) patients previously treated with OC-1 cells.

T Cell Acute Lymphoblastic Leukemia Lymphoma trials by city

Other conditions